Clinical trials: Overweight and Obesity
Morbid Obesity
Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band
The purpose of the study is to evaluate the long term safety of the Swedish Adjustable Gastric Band (SAGB) in subjects with an SAGB in place.
- Trial name
- SAGB-PM (NCT00543140)
- Testing
- REALIZE™ Swedish Adjustable Gastric Band
- Where
- 8 sites in United States
- Volunteers
- 303 people
- Sponsor
- Ethicon Endo-Surgery
Obesity
Pilot Study to Evaluate A Novel Gastric Space Occupying Device
This will be an observational, prospective, non-randomized, pilot study to gain initial device experience on a novel space-occupying device in persons who are overweight or obese. No formal hypothesis testing will be conducted.
- Trial name
- NCT01444274
- Testing
- Obalon Gastric Balloon(s)
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Obalon Therapeutics, Inc.
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection
- Trial name
- NCT07842640
- Testing
- ASC35 Injection B, for subcutaneous use, Tirzepatide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity, Weight Management
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
- Trial name
- NCT07073417
- Testing
- XW003 injection, semaglutide injection
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Overweight and Obesity
Efficacy and Safety of Glucosanol™ in Body Weight Reduction
It was proven in a previous clinical study that Glucosanol™ is effective and safe in reducing weight in the overweight and obese.
- Trial name
- NCT02930668
- Testing
- Glucosanol 350mg, Glucosanol 500mg
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Type 2 Diabetes, Obesity
Balance System Study in Type 2 Diabetic Patients
To evaluate the safety and performance of the BALANCE System in treating patients who have type 2 diabetes and are overweight. Impact on blood glucose levels, weight loss, blood pressure and other clinical and metabolic…
- Trial name
- NCT00872846
- Testing
- BALANCE System intestinal electrical stimulator
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Beta-Stim Ltd.
Dietary Supplement
To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO
The goal of this mechanistic, exploratory study is to compare the effectiveness of Oligomalt to Glucidex 40 after eating in adults with Type 2 Diabetes (T2D) and in otherwise healthy adults with overweight or obesity (HAO).
- Trial name
- LORIS-02 (NCT05963594)
- Testing
- Oligomalt, maltodextrin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity
Safety and Performance of the OTTAVA Robotic System
This study assesses safety and performance of the OTTAVA Robotic System, through 30 days postoperative, in subjects undergoing robotic-assisted Roux-en-Y Gastric Bypass (RYGB) procedure.
- Trial name
- FORTE (NCT06709261)
- Testing
- OTTAVA Robotic System
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Auris Health, Inc.
Obesity, Overweight
Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)
The purpose of this study is to evaluate the effect of SCH 497079 on weight in obese and overweight participants. The primary measure of effectiveness is the change in body weight during treatment.
- Conditions
- Obesity, Overweight, Body Weight
- Trial name
- NCT00642993
- Testing
- SCH 497079
- Volunteers
- 401 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes
The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.
- Trial name
- NCT00650806
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese.
- Trial name
- NCT07738614
- Testing
- Eloralintide, Acetaminophen
- Where
- 2 sites in United States, Singapore
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Noom Coach for Bariatric Health
Mobile technologies/smartphone applications offer a means to effect behavior change without significant obstacles that typically limit implementation of empirically supported therapies (e.g., in-person sessions); however…
- Trial name
- NCT03887078
- Testing
- Noom Coach for Bariatric Health
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Noom Inc.
Overweight , Obesity
A Study of SRSD384 in Overweight or Obese Participants
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in…
- Trial name
- NCT07557355
- Testing
- SRSD384 injection
- Where
- Australia
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Sirius Therapeutics Co., Ltd.
Obesity & Overweight
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity.
- Trial name
- NCT07622810
- Testing
- Bofanglutida, Semaglutide
- Where
- 6 sites in Mexico
- Volunteers
- 352 people
- Sponsor
- Carnot Laboratories
Metabolism and Nutrition Disorder, Overweight or Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants…
- Trial name
- STEP 1 (NCT03548935)
- Testing
- Semaglutide
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 1,961 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Lipodystrophy, Cellulitis
Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat
PURPOSE: To evaluate the efficacy of shock waves extracorporea in improving body contour,decrease fat localized and appearance of gynoid lipodystrophy.
- Conditions
- Lipodystrophy, Cellulitis, Adiposity
- Trial name
- ESWT (NCT03275259)
- Testing
- THORK Shock Wave® (Extracorporeal shock waves)
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Indústria Brasileira Equipamentos Médicos - IBRAMED
Obese
Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03)
The objectives of this clinical study are to determine the tolerance of dietary supplement Lipidrive through the evaluation of several parameters : Various blood biological parameters Urinary parameters Hemodynamic indicators…
- Trial name
- NCT03052062
- Testing
- Lipidrive
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Valbiotis
Obesity
Crave Crush Neuroimaging Study
The purpose of the research is to test whether a gymnemic acids (GA) lozenge will reduce reward region response to intake of high-sugar food and ad lib candy intake and whether the GA lozenge reduced reward region response to…
- Trial name
- NCT02949102
- Testing
- Crave Crush
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.